vitilin 5mg gragea
farmindustria s.a. - gragea - por gragea; trioxisaleno 5.000000 mg; - trioxisaleno
trioxisaleno 5 mg tableta recubierta
laboratorios ac farma s.a. - tableta recubierta
trioxaleno 10 mg
por ; trioxisaleno 10.000000 mg;
alfitar 667 microgramos/ml solución para pulverización cutánea
sesderma s.l. - brea hulla - soluciÓn para pulverizaciÓn cutÁnea - 0,667 mg/ml - brea hulla 0,667 mg - alquitranes
triloxar 5 mg gragea
farmindustria s.a. - laboratorio - gragea - por gragea - - trioxisaleno
piroxgel 6 mg/ml champu
isdin s.a. - brea hulla - champÚ - 6 mg/ml - brea hulla 6 mg - champues medicinales. otros
zincation plus 10 mg/4 mg/ml champu
isdin s.a. - piritiona zincica; brea hulla - champÚ - 10 mg/ml + 4 mg/ml - piritiona zincica 10 mg; brea hulla 4 mg - champúes medicinales
zincation plus 1/0,4% champú 500 ml
plerixafor glenmark 20 mg/ml solucion inyectable efg
glenmark arzneimittel gmbh - plerixafor - soluciÓn inyectable - 20 mg/ml inyectable 1,2 ml - plerixafor 20 mg - plerixafor
plerixafor accord
accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - inmunoestimulantes, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.